-
Kelun Pharmaceutical's Tirofiban Hydrochloride and Sodium Chloride Injection Passed the Consistency Evaluation
Time of Update: 2021-04-28
Product specifications:100ml: tirofiban hydrochloride (calculated as C22H36N2O5S) 5mg and sodium chloride 0.
It has the advantages of rapid onset, definite efficacy, and rapid recovery of platelet function after drug withdrawal.
-
Tylenol Microlab TNM002 monoclonal antibody successfully obtained IND approval from the US FDA
Time of Update: 2021-04-28
, referred to as “Tinomab” and “Trinomab”) announced its self-developed recombinant anti-tetanus toxin monoclonal antibody drug TNM002 Its clinical trial application (IND) was officially approved by the U.
TNM002 is a natural and fully human monoclonal antibody drug developed by Trinomab using its HitmAb® technology platform with independent intellectual property rights.
-
The first Claudin 18.2/PD-L1 double antibody was approved for clinical use
Time of Update: 2021-04-28
Q-1802 is a bispecific antibody that is independently developed by Qiyu Biologics using its antibody engineering technology platform and has independent intellectual property rights that can simultaneously target PD-L1 and Claudin 18.
2/PD-L1 bispecific antibody that passed the US FDA IND.
-
Two exclusive formulations of 600 million anti-allergic drug companies have been reviewed
Time of Update: 2021-04-28
Brand pattern of the terminal desloratadine in China's public medical institutions in 2019Source: Mi Nei. com, China's public medical institutions terminal competition patternThe desloratadine products currently on the market in China include desloratadine tablets, desloratadine dispersible tablets, desloratadine dry suspension, desloratadine capsules, desloratadine syrup and Deloratadine oral solution.
-
Pfizer's BRAF inhibitor approved in China for clinical treatment of colorectal cancer
Time of Update: 2021-04-28
According to the information on the website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, Pfizer's BRAF inhibitor encorafenib hard capsule has obtained an implied license for a clinical trial to develop a treatment for colorectal cancer.
-
Pfizer's PF-06882961 clinical trial application was approved for the treatment of type 2 diabetes
Time of Update: 2021-04-28
Danuglipron (code name: PF-06882961 tablets) is an oral small molecule GLP-1 receptor agonist developed by Pfizer.
The company will also initiate a phase IIb clinical trial to test the efficacy of this oral small molecule GLP-1 receptor agonist in the treatment of patients with NASH.
-
New news from basic medicine
Time of Update: 2021-04-28
On the basis of the "Shandong Provincial Health Commission and Shandong Provincial Market Supervision Administration's Notice on Further Strengthening the Management of the Provision and Use of Essential Medicines in Public Medical Institutions", the proportion of essential medicines used will be further increased and the province's primary medical and health care will be promoted.
-
Osaikang Pharmaceutical's dexrazoxane for injection has been approved
Time of Update: 2021-04-28
On March 17, the official website of the State Administration of Food and Drug Administration showed that Jiangsu Aosaikang Pharmaceutical's dexrazoxane for injection was approved for listing in imitation 3 categories, and it was deemed to have been reviewed.
-
Pfizer and Sanofi "on the list" will the generic drug market be reshuffled?
Time of Update: 2021-04-28
With 17 more varieties, the generic drug market is about to change. Compared with high-priced original research drugs, generic drugs can greatly reduce the burden of patients' medication and the burde
-
Xi'an Janssen established a new business department, Wang Yu promoted to vice president
Time of Update: 2021-04-28
According to a public account report, yesterday, Xi’an Janssen President An Sijia announced to employees that he would integrate and establish a new neuroscience, anti-infection and vaccine product business unit, and promote Wang Yu to vice president and head of this business unit.
-
The first in China! Idea Di AXL Inhibitor Application for Clinical
Time of Update: 2021-04-28
The advantage of AVB-500 is that it has a high affinity for GAS6 ligand, which solves the problem of low selectivity of TKI inhibitors targeting AXL, resulting in off-target toxicity, tumor cell resistance, and low affinity of monoclonal antibodies.
Previously, AVB-500 has shown potential efficacy in a phase Ib clinical trial for patients with platinum-resistant ovarian cancer (PROC).
-
AstraZeneca's CLL drug Calquence is approved by NICE in the UK
Time of Update: 2021-04-28
CompilationFan DongdongA few days ago, the National Institute of Health and Clinical Optimization (NICE) decided to recommend AstraZeneca’s BTK inhibitor Calquence (Acalabrutinib) into the British National Health Service (NHS) for the treatment of certain adult chronic lymphocytic leukemia (CLL).
-
CStone's platinib enters China for approval and is expected to usher in the first approved RET inhibitor
Time of Update: 2021-04-28
Public information shows that the indication for this application of the drug is a locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patient who has previously received platinum-containing chemotherapy and has a positive RET gene fusion.
-
The latest announcement of Gansu Provincial Food and Drug Administration is related to enterprises and scientific research institutes inside and outside the province!
Time of Update: 2021-04-28
On March 22, the Gansu Provincial Food and Drug Administration issued a document to encourage enterprises and scientific research institutes inside and outside the province to participate in the formu
-
Jinling Pharmaceutical's ferrous succinate tablets obtained the consistency evaluation of the National Food and Drug Administration
Time of Update: 2021-04-27
On March 23, Jinling Pharmaceutical issued an announcement stating that the branch Jinling Pharmaceutical Factory had recently received a notice of acceptance of the consistency evaluation of ferrous succinate tablets issued by the State Food and Drug Administration.
Jinling Pharmaceutical Factory first obtained the Drug Registration Approval for this product in 2002.
-
Huahai Pharmaceutical's voriconazole for injection was approved for clinical use
Time of Update: 2021-04-27
Voriconazole for injection is a broad-spectrum triazole antifungal drug; the original research company is Pfizer, which was approved for domestic marketing in October 2004.
-
How to see a doctor in an Internet hospital?
Time of Update: 2021-04-27
Xiong Xianjun, Director of the Medical Service Management Department of the National Medical Insurance Administration: The medical and drug expenses incurred by the insured person in the designated "Internet +" medical service follow- up prescriptions in the designated area of the coordination area can be given in accordance with the existing treatment policies of offline medical insurance Payment, with prescriptions outside designated medical institutions, you can also pick up medicines at local designated pharmacies .
-
Home-made cervical cancer vaccine landed in Beijing
Time of Update: 2021-04-27
Today, the domestically-made bivalent cervical cancer vaccine started its first dose in Beijing.
In the physical examination and rehabilitation center of the Civil Aviation General Hospital, Zhao Fang, deputy chief physician of the Department of Gynecology of Jishuitan Hospital, received the first shot of Beijing vaccine.
-
Sinopharm: Medical Device Annual Revenue Announcement
Time of Update: 2021-04-27
Facing the national centralized procurement, the latest strategy is announced According to the announcement of Sinopharm Holdings, in 2020, the strict prevention and control measures adopted by hospitals will restrict the development of daily medical operations and hospitalization services, which will have a phased impact on the sales and product structure of the medical device business.
-
Roche's PD-L1 antibody Tecentriq in the Phase 3 clinical trial of NSCLC patients reached the primary endpoint
Time of Update: 2021-04-27
On March 22, Genentech, a subsidiary of Roche, announced that its PD-L1 antibody Tecentriq (atezolizumab, atelizumab) will be used for the treatment of early stage non-small cell lung cancer (NSCLC) patients in Phase 3 clinical trials.
